Shenzhen Hepalink Pharmaceutical Group

Shenzhen Hepalink Pharmaceutical Group

Founded in 1998 by spouses Li Li and Li Tan, Shenzhen Hepalink Pharmaceutical Group secured its structural advantage by becoming the primary heparin API supplier to global pharmaceutical firms. The company listed on the Shenzhen Stock Exchange in 2010 and completed a Hong Kong dual-listing in 2020. Hepalink's investment activities are inseparable from its operating engine — the group recycles cash flows from bulk-drug manufacturing and finished-dosage injectables into adjacent biotechnology assets. Hepalink deploys capital across three business lines: heparin industrial chain management, biologic contract development and manufacturing (CDMO), and innovative drug investments. The heparin franchise runs from crude sourcing in China through FDA-approved manufacturing sites in Wisconsin and Oklahoma. Through its Cytovance and SPL subsidiaries in the United States, Hepalink provides mammalian and microbial CDMO services. The group's operational centers span Shenzhen (headquarters and Pingshan Industrial Park), Hong Kong, Wisconsin, and Oklahoma City. The group targets early-to-mid-stage therapeutic assets with a focus on anti-coagulants, oncology, and immunology. Major shareholder Shenzhen Leren Scientific & Technological Co., Ltd. anchors Hepalink's governance structure. Li Tan represents the family's institutional engagement through membership in the Asia Philanthropy Circle and the China Healthcare Investment 50 Forum, where Executive Director Frank Sun holds a board seat. The Li Foundation serves as the family's primary philanthropic vehicle. No recent transactional deployment data is publicly disclosed beyond the group's regulatory filings on the Shenzhen and Hong Kong exchanges. Hepalink's architecture blends a publicly traded industrial corporation with the investment posture of a strategic asset owner. The group's factory-level heparin dominance — combined with US-based biologic manufacturing capacity — gives it a sourcing advantage and regulatory footprint that pure financial investors cannot replicate. This dual identity, as both operating company and strategic capital allocator, defines how Hepalink accesses deal flow and underwrites biologic platform risk.